Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy(Memorial Sloan Kettering Cancer Center), Robert Chen(City Of Hope National Medical Center), Kevin Kwei(Stanford University), Catherine Thiéblemont(Université Paris Cité), Peter Martin(Northwestern University), Franck Morschhauser(Hôpital Claude Huriez), Israel Arango‐Hisijara(AbbVie (United States)), Jacqueline C. Barrientos(Mount Sinai Medical Center), Leo W.K. Cheung(AbbVie (United States)), Shuo Ma(Nantong University), Sven de Vos(University of California, Los Angeles), Morton Coleman(Cornell University), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Stephen D. Smith(Seattle Cancer Care Alliance), Graham P. Collins(Churchill Hospital), Shiquan Wu(AbbVie (United States)), Shachar Peles(Medical College of Wisconsin), Bernhard Hauns(AbbVie (United States)), Elizabeth Chong(AbbVie (United States))
Cited by 102
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k